www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Report on Management's transactions with ALK-Abelló A/S B shares and asso-ciated securities

March 18, 2016

PDF Version

Supporting Materials:
FM_15_16UK_18032016.pdf

Copenhagen, 2016-03-18 13:21 CET (GLOBE NEWSWIRE) --  

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 28(a) of the Danish Securities Trading Act, ALK-Abelló A/S shall report the following transactions under securities identification code (ISIN) DK0060027142. The announcement is based on the allotments of share options and conditional shares which ALK has granted to the Company’s Board of Management on 17 March 2016 in accordance with the incentive pay guidelines adopted at the Company’s annual general meeting on 10 March 2016: 

 
Name
 
Position
 
Transaction
 
Number
Market value DKK
Henrik JacobiMember of Board
of Management
Allotted share options2,180 
  Allotted conditional shares466 
Total   906,200

   

 
Name
 
Position
 
Transaction
 
Number
Market value, DKK
Søren NiegelMember of Board
of Management
Allotted share options 
2,180
 
  Allotted conditional shares466 
Total   906,200

   

 
Name
 
Position
 
Transaction
 
Number
Market value DKK
Flemming
Pedersen
Member of Board
of Management
Allotted share options 
2,180
 
  Allotted conditional shares466 
Total   906,200

   

 
Name
 
Position
 
Transaction
 
Number
Market value, DKK
Helle SkovMember of Board
of Management
Allotted share options 
2,180
 
  Allotted conditional shares466 
Total   906,200

  

The shares are traded at NASDAQ Copenhagen. 

ALK-Abelló A/S  

Steen Riisgaard
Chairman 

If you require further information, please feel free to contact Steen Riisgaard, Chairman of the Board, tel. +45 4574 7576.

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved